Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Cash from Investing Activities of $36.3 million for Q1 2026, up 183.06% year-over-year from $12.8 million in Q1 2025, and up 23.06% quarter-over-quarter from $29.5 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $36.3 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 183.06% year-over-year to $36.3 million; the TTM figure through Mar 2026 stood at $94.0 million (up 201.39% YoY), while the FY2025 annual figure was $14.0 million, down 81.44% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $36.3 million, up from $29.5 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $123.2 million in Q2 2023, with the low at -$228.2 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is $20.9 million (2023), against an average of -$1.2 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 709264.29% in 2022, then jumped 2661.59% in 2023.
- Amylyx Pharmaceuticals' Cash from Investing Activities stood at -$228.2 million in 2022, then jumped by 109.17% to $20.9 million in 2023, then surged by 210.54% to $65.0 million in 2024, then tumbled by 54.65% to $29.5 million in 2025, then climbed by 23.06% to $36.3 million in 2026.
- Business Quant data shows AMLX's Cash from Investing Activities at $36.3 million in Q1 2026, $29.5 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | -149.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -149.80 Mn |
| Jun 30, 2026 | -149.80 Mn |
| Mar 31, 2026 | 36.26 Mn |
| Mar 31, 2026 | 36.26 Mn |
| Dec 31, 2025 | 29.47 Mn |
| Dec 31, 2025 | 29.47 Mn |
| Sep 30, 2025 | 5.24 Mn |
| Sep 30, 2025 | 5.24 Mn |
| Jun 30, 2025 | 22.99 Mn |
| Jun 30, 2025 | 22.99 Mn |
| Mar 31, 2025 | -43.66 Mn |
| Mar 31, 2025 | -43.66 Mn |
| Dec 31, 2024 | 64.98 Mn |
| Dec 31, 2024 | 64.98 Mn |
| Sep 30, 2024 | 38.82 Mn |
| Sep 30, 2024 | 38.82 Mn |
| Jun 30, 2024 | -28.96 Mn |
| Jun 30, 2024 | -28.96 Mn |
| Mar 31, 2024 | 819,000.00 |
| Mar 31, 2024 | 819,000.00 |